Elmind Capital, LP
- SEC CIK
- 0002052213
- Latest filing
- Aug 14, 2026
Holdings in Q4 2025
Holdings as of Dec 31, 2025, filed Feb 17, 2026. Long positions only.
- Positions
- 34
- No filing for Q3 2025
- Portfolio value
- $338.9M
- No filing for Q3 2025
Elmind Capital, LP did not file a 13F for Q3 2025, so these holdings cannot be compared with the previous quarter and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| COGTCogent Biosciences, Inc. | COM | 1,170,740 | $41.6M | 12.3% | – | – | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 1,855,000 | $39.0M | 11.5% | – | – | History |
| VRDNViridian Therapeutics, Inc. | COM | 858,631 | $26.7M | 7.9% | – | – | History |
| VERAVera Therapeutics, Inc. | CL A | 482,500 | $24.4M | 7.2% | – | – | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 865,000 | $23.5M | 6.9% | – | – | History |
| CGONCG Oncology, Inc. | COM | 492,500 | $20.4M | 6.0% | – | – | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 2,150,000 | $16.8M | 4.9% | – | – | History |
| PCVXVaxcyte, Inc. | COM | 291,500 | $13.4M | 4.0% | – | – | History |
| BEAMBeam Therapeutics Inc. | COM | 476,338 | $13.2M | 3.9% | – | – | History |
| PHVSPharvaris N.V. | COM | 475,750 | $13.2M | 3.9% | – | – | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 801,300 | $12.9M | 3.8% | – | – | History |
| DVAXDynavax Technologies Corp | COM NEW | 679,900 | $10.5M | 3.1% | – | – | History |
| TYRATyra Biosciences, Inc. | COM | 350,000 | $9.20M | 2.7% | – | – | History |
| NRIXNurix Therapeutics, Inc. | COM | 460,000 | $8.73M | 2.6% | – | – | History |
| WVEWave Life Sciences, Inc. | SHS | 447,846 | $7.61M | 2.2% | – | – | History |
| MBXMBX Biosciences, Inc. | COM | 211,000 | $6.65M | 2.0% | – | – | History |
| KRYSKrystal Biotech, Inc. | COM | 22,000 | $5.42M | 1.6% | – | – | History |
| UTHRUnited Therapeutics Corp | COM | 11,000 | $5.36M | 1.6% | – | – | History |
| BMRNBiomarin Pharmaceutical Inc | COM | 82,000 | $4.87M | 1.4% | – | – | History |
| RLAYRelay Therapeutics, Inc. | COM | 536,946 | $4.54M | 1.3% | – | – | History |
| TVTXTravere Therapeutics, Inc. | COM | 110,000 | $4.20M | 1.2% | – | – | History |
| PTGXProtagonist Therapeutics, Inc | COM | 38,000 | $3.32M | 1.0% | – | – | History |
| CGEMCullinan Therapeutics, Inc. | COM | 310,000 | $3.21M | 0.9% | – | – | History |
| LQDALiquidia Corp | COM NEW | 90,000 | $3.10M | 0.9% | – | – | History |
| CTMXCytomX Therapeutics, Inc. | COM | 700,000 | $2.98M | 0.9% | – | – | History |
| URGNUroGen Pharma Ltd. | COM | 100,000 | $2.34M | 0.7% | – | – | History |
| IMCRImmunocore Holdings plc | ADS | 58,248 | $2.02M | 0.6% | – | – | History |
| DSGNDesign Therapeutics, Inc. | COM | 207,900 | $1.95M | 0.6% | – | – | History |
| ENGNenGene Therapeutics Inc. | COM | 210,000 | $1.90M | 0.6% | – | – | History |
| ALECAlector, Inc. | COM | 900,000 | $1.40M | 0.4% | – | – | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 112,000 | $1.35M | 0.4% | – | – | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 50,000 | $1.26M | 0.4% | – | – | History |
| SUPNSupernus Pharmaceuticals, Inc. | COM | 20,000 | $994.0K | 0.3% | – | – | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 30,000 | $744.5K | 0.2% | – | – | History |